Correspondence 0000950170-25-052253 from Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc.
Date: April 8, 2025 · CIK: 0001607678 · Accession: 0000950170-25-052253
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-37355
Referenced dates: March 31, 2025
Letter
Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego, CA 92121 858-704-4660 April 8, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Eric Atallah Kevin Kuhar Re: Viking Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-37355 Ladies and Gentlemen: This letter responds to the comments of the Staff (the “ Staff ”) of the Securities and Exchange Commission (the “ Commission ”) to Greg Zante, Chief Financial Officer of Viking Therapeutics, Inc., a Delaware corporation (the “ Company ”), in the comment letter dated March 31, 2025 (the “ Comment Letter ”) relating to the Company’s Annual Report on Form 10-K (File No. 001-37355) for the fiscal year ended December 31, 2024 filed with the Commission on February 26, 2025. Set forth below are the Staff’s comments (in bold italics) and the Company’s responses to each comment, organized as set forth in the Comment Letter. Form 10-K for Fiscal Year Ended December 31, 2024 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations Research and Development Expenses, page 65 1. We note from the disclosures on page 5 that you have four programs in various stages of development. Please provide disclosures to be included in future filings that disclose the costs incurred during each period presented for each of your key research and development programs separately. If you do not track your research and development costs by program, revise to disclose that fact and explain why you do not maintain and evaluate research and development costs by program. For amounts that are not tracked by program, provide a break down by nature or type of research and development expenses incurred which should reconcile to total research and development expense on the Statements of Operations. The Company respectfully advises the Staff that it does not track its research and development costs by program but rather only by external and internal development costs, because it manages its research and development efforts dynamically, taking into account large unmet medical need, scientific data, probability of technical and regulatory success and other considerations. The Company will include in its
future filings disclosures consistent with the foregoing. In addition, the Company respectfully advises the Staff that it will provide in its future filings a break down by nature or type of research and development expenses incurred (specifically, internal development costs and external development costs) which will reconcile to total research and development expense on the Statements of Operations. General and Administrative Expenses, page 66 2. We note your discussion of the changes in general and administrative expenses cites multiple factors without any quantification of the individual factors. Please provide disclosures to be included in future filings to quantify the impact of each material contributing factor and explain the reasons driving these changes. Refer to Item 303 (a) to (c) of Regulation S-K for guidance. The Company respectfully advises the Staff that, as required by Item 303(a) to (c) of Regulation S-K, it will include in its discussion of changes in research and development expenses and general and administrative expenses in future filings disclosures that quantify the impact of each material contributing factor and explain the reasons driving the changes. We appreciate the time that you have taken to review our public filings. Please contact me if you have any further comments or need additional information with respect to the filing. The Company’s future filings will reflect the responses set forth in this letter, as applicable. Thank you for your assistance. Sincerely, Viking Therapeutics, Inc.
By: /s/ Greg Zante
Name: Greg Zante Title: Chief Financial Officer cc: Steve Rapattoni, Marcum LLP Jeffrey T. Hartlin, Paul Hastings LLP Samantha H. Eldredge, Paul Hastings LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego, CA 92121 858-704-4660 April 8, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Eric Atallah Kevin Kuhar Re: Viking Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-37355 Ladies and Gentlemen: This letter responds to the comments of the Staff (the “ Staff ”) of the Securities and Exchange Commission (the “ Commission ”) to Greg Zante, Chief Financial Officer of Viking Therapeutics, Inc., a Delaware corporation (the “ Company ”), in the comment letter dated March 31, 2025 (the “ Comment Letter ”) relating to the Company’s Annual Report on Form 10-K (File No. 001-37355) for the fiscal year ended December 31, 2024 filed with the Commission on February 26, 2025. Set forth below are the Staff’s comments (in bold italics) and the Company’s responses to each comment, organized as set forth in the Comment Letter. Form 10-K for Fiscal Year Ended December 31, 2024 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations Research and Development Expenses, page 65 1. We note from the disclosures on page 5 that you have four programs in various stages of development. Please provide disclosures to be included in future filings that disclose the costs incurred during each period presented for each of your key research and development programs separately. If you do not track your research and development costs by program, revise to disclose that fact and explain why you do not maintain and evaluate research and development costs by program. For amounts that are not tracked by program, provide a break down by nature or type of research and development expenses incurred which should reconcile to total research and development expense on the Statements of Operations. The Company respectfully advises the Staff that it does not track its research and development costs by program but rather only by external and internal development costs, because it manages its research and development efforts dynamically, taking into account large unmet medical need, scientific data, probability of technical and regulatory success and other considerations. The Company will include in its future filings disclosures consistent with the foregoing. In addition, the Company respectfully advises the Staff that it will provide in its future filings a break down by nature or type of research and development expenses incurred (specifically, internal development costs and external development costs) which will reconcile to total research and development expense on the Statements of Operations. General and Administrative Expenses, page 66 2. We note your discussion of the changes in general and administrative expenses cites multiple factors without any quantification of the individual factors. Please provide disclosures to be included in future filings to quantify the impact of each material contributing factor and explain the reasons driving these changes. Refer to Item 303 (a) to (c) of Regulation S-K for guidance. The Company respectfully advises the Staff that, as required by Item 303(a) to (c) of Regulation S-K, it will include in its discussion of changes in research and development expenses and general and administrative expenses in future filings disclosures that quantify the impact of each material contributing factor and explain the reasons driving the changes. We appreciate the time that you have taken to review our public filings. Please contact me if you have any further comments or need additional information with respect to the filing. The Company’s future filings will reflect the responses set forth in this letter, as applicable. Thank you for your assistance. Sincerely, Viking Therapeutics, Inc. By: /s/ Greg Zante Name: Greg Zante Title: Chief Financial Officer cc: Steve Rapattoni, Marcum LLP Jeffrey T. Hartlin, Paul Hastings LLP Samantha H. Eldredge, Paul Hastings LLP